Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

Population pharmacokinetic (PK) and exposure‐safety analyses of alisertib were performed in children enrolled in 2 clinical trials: NCT02444884 and NCT01154816. NCT02444884 was a dose‐finding study in children with relapsed/refractory solid malignancies (phase 1) or neuroblastomas (phase 2). Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Mould, Diane R., Yuan, Ying, Fox, Elizabeth, Greengard, Emily, Faller, Douglas V., Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274904/
https://www.ncbi.nlm.nih.gov/pubmed/34435684
http://dx.doi.org/10.1002/jcph.1958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274904/
https://www.ncbi.nlm.nih.gov/pubmed/34435684
http://dx.doi.org/10.1002/jcph.1958

Ejemplares similares